Showing results (211-220 of 398) with videos related to

Sort By:
Pageof 40
Infectious Diseases and Therapy|December 14, 2021
Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical TrialsPedro L Gonzalez, Urania Rappo, Karthik Akinapelli, et al.
Brain Research|September 28, 1998
A comparison of delta 9-THC and anandamide induced c-fos expression in the rat forebrainI S McGregor, J C Arnold, M F Weber, et al.
Crohn'S & Colitis 360|February 13, 2023
Attitudes and Knowledge of Australian Gastroenterologists Around the Use of Medicinal Cannabis for Inflammatory Bowel DiseaseMelissa J Benson, Sarah V Abelev, Crispin J Corte, et al.
Proceedings. AMIA Symposium|November 24, 1999
The accessibility of information systems for patients: use of touchscreen information systems by 345 patients with cancer in ScotlandJ Pearson, R Jones, A Cawsey, et al.
Neurochemistry International|May 26, 2009
Effects of typical (haloperidol) and atypical (risperidone) antipsychotic agents on protein expression in rat neural stem cellsMohammed A Kashem, Rahnuma Ummehany, Wataru Ukai, et al.
The European Journal of Neuroscience|June 4, 2009
Involvement of hypothalamic peptides in the anorectic action of the CB receptor antagonist rimonabant (SR 141716)Aaron N A Verty, Wee M Boon, Paul E Mallet, et al.
The International Journal of Neuropsychopharmacology|September 30, 2009
A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc miceLeonora E Long, Rose Chesworth, Xu-Feng Huang, et al.
Neurochemistry International|September 22, 2012
Long-term daily access to alcohol alters dopamine-related synthesis and signaling proteins in the rat striatumMohammed Abul Kashem, Selina Ahmed, Ranjana Sarker, et al.
Australian Journal of General Practice|September 30, 2021
Medicinal cannabis in the treatment of chronic painLuke A Henderson, Vicki Kotsirilos, Elizabeth A Cairns, et al.
Psychopharmacology|August 24, 2010
Residual social, memory and oxytocin-related changes in rats following repeated exposure to γ-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combinationPetra S van Nieuwenhuijzen, Leonora E Long, Glenn E Hunt, et al.
Pageof 40